Brian Skorney
Stock Analyst at Baird
(3.38)
# 967
Out of 5,135 analysts
117
Total ratings
46.99%
Success rate
5.23%
Average return
Main Sectors:
Stocks Rated by Brian Skorney
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $80 → $88 | $102.83 | -14.42% | 6 | Dec 9, 2025 | |
| ANRO Alto Neuroscience | Maintains: Outperform | $16 → $22 | $19.26 | +14.23% | 4 | Nov 13, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $21 → $15 | $17.88 | -16.11% | 13 | Nov 4, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Outperform | $58 → $62 | $43.69 | +41.91% | 5 | Sep 26, 2025 | |
| BHVN Biohaven | Maintains: Outperform | $57 → $52 | $11.48 | +352.96% | 4 | Aug 12, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $180 → $186 | $127.76 | +45.59% | 5 | Jul 31, 2025 | |
| SLNO Soleno Therapeutics | Maintains: Outperform | $105 → $121 | $38.50 | +214.29% | 5 | Jul 11, 2025 | |
| DYN Dyne Therapeutics | Maintains: Outperform | $46 → $32 | $15.28 | +109.42% | 2 | Jun 18, 2025 | |
| BIIB Biogen | Maintains: Outperform | $300 → $255 | $195.62 | +30.35% | 17 | May 2, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $652 → $587 | $793.53 | -26.03% | 15 | Apr 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $100 | $155.27 | -35.60% | 3 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $10.36 | +189.72% | 1 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $20 | $13.89 | +43.99% | 6 | Nov 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $26.58 | -5.94% | 1 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $215 | $373.36 | -42.41% | 4 | Sep 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $6.28 | +345.86% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $39 | $8.04 | +385.07% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $41.66 | +51.22% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $280 → $325 | $477.32 | -31.91% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 | $26.28 | -61.95% | 2 | Aug 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $270 | $0.53 | +50,843.40% | 1 | May 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $6 | $3.41 | +75.95% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $300 | $1.06 | +28,201.89% | 3 | May 7, 2018 |
Mirum Pharmaceuticals
Dec 9, 2025
Maintains: Outperform
Price Target: $80 → $88
Current: $102.83
Upside: -14.42%
Alto Neuroscience
Nov 13, 2025
Maintains: Outperform
Price Target: $16 → $22
Current: $19.26
Upside: +14.23%
Sarepta Therapeutics
Nov 4, 2025
Maintains: Neutral
Price Target: $21 → $15
Current: $17.88
Upside: -16.11%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Outperform
Price Target: $58 → $62
Current: $43.69
Upside: +41.91%
Biohaven
Aug 12, 2025
Maintains: Outperform
Price Target: $57 → $52
Current: $11.48
Upside: +352.96%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Outperform
Price Target: $180 → $186
Current: $127.76
Upside: +45.59%
Soleno Therapeutics
Jul 11, 2025
Maintains: Outperform
Price Target: $105 → $121
Current: $38.50
Upside: +214.29%
Dyne Therapeutics
Jun 18, 2025
Maintains: Outperform
Price Target: $46 → $32
Current: $15.28
Upside: +109.42%
Biogen
May 2, 2025
Maintains: Outperform
Price Target: $300 → $255
Current: $195.62
Upside: +30.35%
Regeneron Pharmaceuticals
Apr 30, 2025
Maintains: Neutral
Price Target: $652 → $587
Current: $793.53
Upside: -26.03%
Feb 12, 2025
Maintains: Neutral
Price Target: $95 → $100
Current: $155.27
Upside: -35.60%
Dec 13, 2024
Initiates: Outperform
Price Target: $30
Current: $10.36
Upside: +189.72%
Nov 26, 2024
Maintains: Outperform
Price Target: $26 → $20
Current: $13.89
Upside: +43.99%
Oct 31, 2024
Initiates: Outperform
Price Target: $25
Current: $26.58
Upside: -5.94%
Sep 25, 2024
Reiterates: Underperform
Price Target: $215
Current: $373.36
Upside: -42.41%
Jun 13, 2024
Initiates: Outperform
Price Target: $28
Current: $6.28
Upside: +345.86%
Mar 6, 2024
Maintains: Outperform
Price Target: $34 → $39
Current: $8.04
Upside: +385.07%
Dec 8, 2023
Initiates: Outperform
Price Target: $63
Current: $41.66
Upside: +51.22%
May 2, 2023
Maintains: Neutral
Price Target: $280 → $325
Current: $477.32
Upside: -31.91%
Aug 3, 2021
Downgrades: Neutral
Price Target: $10
Current: $26.28
Upside: -61.95%
May 20, 2021
Initiates: Outperform
Price Target: $270
Current: $0.53
Upside: +50,843.40%
Feb 26, 2021
Downgrades: Neutral
Price Target: $18 → $6
Current: $3.41
Upside: +75.95%
May 7, 2018
Maintains: Outperform
Price Target: $600 → $300
Current: $1.06
Upside: +28,201.89%